Medical Dialogues presents a rare disease series, delving into the realm of uncommon medical conditions. Rare diseases are ...

Dasiglucagon is a glucagon analog formulated in a ready-to-use aqueous solution. It is being reviewed for congenital hyperinsulinism (CHI), a rare genetic disease that affects newborns and children ...

FDA lifts partial clinical holds on ersodetug for the treatment of congenital HI; Phase 3 sunRIZE study to proceed in the U.S.Phase 3 study for ...

Most infants did not conform to the classical phenotype of being LGA, with a high prevalence of preterm and SGA infants likely as a result of perinatal-stress hyperinsulinism. Most infants were not ...

Analyst Jason Butler of JMP Securities reiterated a Buy rating on Rezolute (RZLT – Research Report), retaining the price target of $7.00.

(Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed t Phase 3 clinical study of RZ358 underway in patients with congenital hyperinsulinism ...

FDA lifts partial clinical holds on ersodetug for the treatment of congenital HI; Phase 3 sunRIZE study to proceed in the U.S. Phase 3 study for ersodetug for the treatment of tumor HI expected to com ...

the ability of ersodetug to become an effective treatment for congenital hyperinsulinism, the effectiveness or future effectiveness of ersodetug for the treatment of congenital hyperinsulinism ...

“We are thrilled to close out the year with FDA alignment to advance ersodetug in two Phase 3 rare disease programs for the treatment of hypoglycemia resulting from congenital and acquired forms of ...

We look forward to progressing both Phase 3 studies and remain excited at the prospect of ersodetug as a best-in-class treatment for hyperinsulinism ... Milestones Congenital HI U.S. Food and ...